Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in castration-resistant bone metastatic prostate cancer evaluating the tumor microenvironment
2014-004485-21Phase 2Completed
- Sponsor
- HeCOG
- Start
- May 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabazitaxel in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC), sponsored by HeCOG. Primary endpoint: Molecular effects of cabazitaxel on the tumor microenvironment and correlation with outcome. Started May 2015; status: completed.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2014-004485-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004485-21.